At­las, New­path throw $125M be­hind a new ap­proach to gene edit­ing from the field’s biggest names

4 years ago
Cell/Gene Tx

Lis­ten up phar­ma: Au­dio con­tent from stream­ing mu­sic to pod­casts is on the rise — and so are ad op­por­tu­ni­ties

4 years ago
Pharma
Marketing

Q&A: As sci­ence gets its mo­ment, J&J’s glob­al brand stew­ard Seema Ku­mar aims to am­pli­fy the peo­ple be­hind the ...

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Bris­tol My­ers taps young NBA play­er to raise heart con­di­tion aware­ness; Pfiz­er, J&J top ...

4 years ago
Pharma
Marketing

Epizyme rolls out rare blood can­cer ef­fort with pa­tients' sto­ries and friend­ly dig­i­tal coach

4 years ago
Pharma
Marketing

Ex­clu­sive: Big-name aca­d­e­mics and in­vestors are qui­et­ly prepar­ing a slate of new (epi)genome edit­ing com­pa­nies

4 years ago
Cell/Gene Tx
In Focus

UK's Syn­thace rais­es $35M in Se­ries C; On­col­o­gy and in­flam­ma­to­ry dis­ease biotech De­ka hauls in $20M Se­ries A

4 years ago
News Briefing

An­oth­er one bites the dust: No­var­tis, Mol­e­c­u­lar Part­ners and their an­tivi­ral get the boot from NIH Covid study

4 years ago
Coronavirus

Covid-19 roundup: Pfiz­er li­cens­es its pill to the Med­i­cines Patent Pool; NYC joins states in au­tho­riz­ing boost­ers for ...

4 years ago
FDA+
Coronavirus

CRISPR, Vi­a­Cyte beat Ver­tex to the clin­ic with di­a­betes cell ther­a­py that evades the im­mune sys­tem

4 years ago
R&D
Cell/Gene Tx

In quest to elim­i­nate trop­i­cal dis­eases, Mer­ck KGaA will sub­mit an­ti-worm­ing drug for ap­proval in young chil­dren

4 years ago
Pharma

A Czech biotech bets big on ris­ing ADC play­er LegoChem as part of li­cens­ing pact aimed at sol­id tu­mors

4 years ago
Deals

First in­ter­change­able biosim­i­lar launch­es in the US with a tiny dis­count on list price

4 years ago
Pharma

CBC Group es­tab­lish­es new fund to meet Chi­na's boom­ing life sci­ences re­al es­tate de­mand

4 years ago
Financing
China

Out to prove the next big I/O tar­get, Im­mu­ni­tas' chief deal­mak­er steps up to CEO role

4 years ago
People
R&D

ICER finds un­sub­stan­ti­at­ed drug price in­creas­es cost US $1.67B in 2020, but over­all net in­creas­es low­er than years ...

4 years ago
Pharma

Backed by Sean Harp­er and Beth Sei­den­berg, an LA biotech scores a mas­sive $250M crossover ahead of 2022 IPO

4 years ago
Financing

Mer­ck ap­plies DIY mind­set to can­cer screen­ings, adding to in­dus­try post-pan­dem­ic ef­forts

4 years ago
Pharma
Marketing

'I bleed Bio­gen': Just months af­ter the big biotech was slammed fol­low­ing the con­tro­ver­sial OK of ad­u­canum­ab, R&D ...

4 years ago
R&D

Eye­ing an ac­cel­er­at­ed BLA, Phase­Bio says its mon­o­clon­al an­ti­body re­versed the dan­ger­ous ef­fects of As­traZeneca's ...

4 years ago
R&D

Cas­sa­va be­ing in­ves­ti­gat­ed by un­named 'gov­ern­ment agen­cies'; Rock­et Phar­ma gives up­dat­ed da­ta on Danon dis­ease

4 years ago
News Briefing

Bris­tol My­ers and Janssen race to­ward PhI­II with a next-gen blood thin­ner

4 years ago
R&D

Eye dis­ease spe­cial­ists ven­ture in­to M&A with a buy­out deal worth up to $126M

4 years ago
Deals

As­traZeneca, Mod­er­na start to raise the cur­tain on a new mR­NA heart drug — but ef­fi­ca­cy will have to wait

4 years ago
R&D
Cell/Gene Tx
First page Previous page 613614615616617618619 Next page Last page
A service from the Financial Times